Trial Profile
A Randomised controlled trial to evaluate the non-inferiority of switching to Rilpivirine compared to the Ritonavir-boosted protease inhibitors in HIV-infected patients
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 29 Aug 2018
Price :
$35
*
At a glance
- Drugs Rilpivirine (Primary) ; Ritonavir
- Indications HIV infections
- Focus Therapeutic Use
- 29 Aug 2018 New trial record
- 27 Jul 2018 Primary endpoint (Proportion of patients with undetectable HIV RNA at 48 weeks, with a non-inferiority margin of 12%) has been met, according to the results presented at the 22nd International AIDS Conference
- 27 Jul 2018 Results presented at the 22nd International AIDS Conference